BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34872098)

  • 1. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
    PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
    Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
    Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.
    Benjamini O; Gershon R; Bar-Haim E; Lustig Y; Cohen H; Doolman R; Kedmi M; Ribakovsky E; Kneller A; Hod T; Erez N; Levy I; Rahav G; Avigdor A
    Eur J Haematol; 2023 Jan; 110(1):99-108. PubMed ID: 36208015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
    Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
    Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
    Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
    Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
    Molica S; Tam C; Polliack A
    Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
    Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
    Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination.
    Lee HK; Hoechstetter MA; Buchner M; Pham TT; Huh JW; Müller K; Zange S; von Buttlar H; Girl P; Wölfel R; Brandmeier L; Pfeuffer L; Furth PA; Wendtner CM; Hennighausen L
    Blood Adv; 2023 May; 7(10):2214-2227. PubMed ID: 36630562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
    Zaleska J; Kwasnik P; Paziewska M; Purkot J; Szabelak A; Jurek M; Masny N; Dziatkiewicz I; Pronobis-Szczylik B; Piebiak A; Szymczyk A; Jarosz-Chudzik K; Bolkun L; Kozlowska K; Piszcz J; Subocz E; Halka J; Bator M; Kalicinska E; Wrobel T; Usnarska-Zubkiewicz L; Rybka J; Deren-Wagemann I; Szyca-Smieszniak M; Dybko J; Hus I; Pula B; Cichocka E; Rymko M; Zdunczyk D; Ziarkiewicz M; Basak GW; Bullinger L; Giannopoulos K
    Int J Cancer; 2023 Feb; 152(4):705-712. PubMed ID: 35830214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
    Diamantopoulos PT; Kontandreopoulou CN; Stafylidis C; Vlachopoulou D; Giannakopoulou N; Vardaka M; Mpouhla A; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
    Ann Hematol; 2022 Dec; 101(12):2711-2717. PubMed ID: 36271935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.